Serina Therapeutics Appoints Dr. Jay Venkatesan to its Board of Directors
12 févr. 2025 16h15 HE
|
Serina Therapeutics, Inc.
HUNTSVILLE, AL, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug...
Serina Therapeutics Receives Second $5 Million Tranche to Strengthen Cash Position Ahead of Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients
03 févr. 2025 16h30 HE
|
Serina Therapeutics, Inc.
HUNTSVILLE, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company, today announced the successful closing of the second...
Serina Therapeutics Announces Sale of UniverXome Subsidiary
15 janv. 2025 16h05 HE
|
Serina Therapeutics, Inc.
- Transaction eliminates $11.2 million in debt, strengthening financial position - HUNTSVILLE, AL, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics Inc. (“Serina”) (NYSE American: SER), a...
Serina Therapeutics Welcomes Karen J. Wilson to its Board of Directors
14 janv. 2025 17h25 HE
|
Serina Therapeutics, Inc.
HUNTSVILLE, AL, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug...
Serina Therapeutics to Present at Tribe Public’s Webinar Event "Enabling Continuous Drug Delivery for Parkinson's Disease & Beyond" on Wednesday, December 18, 2024
16 déc. 2024 06h00 HE
|
Serina Therapeutics, Inc.
Meet with Serina’s CEO Steven A. LedgerParkinson's disease is a progressive neurological disorder that primarily affects movementContinuous dopaminergic stimulation (CDS) has been shown to reduce the...
Serina Therapeutics to Present at the 3rd Annual LNP Immunogenicity & Toxicity Summit
11 déc. 2024 06h05 HE
|
Serina Therapeutics, Inc.
HUNTSVILLE, AL, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug...
Serina Therapeutics Secures $10 Million Financing to Continue Advancing Lead IND Candidate into Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients
02 déc. 2024 17h22 HE
|
Serina Therapeutics, Inc.
HUNTSVILLE, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company, today announced a $10 million equity financing with...
Serina Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights
12 nov. 2024 17h00 HE
|
Serina Therapeutics, Inc.
HUNTSVILLE, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate SER-252 for advanced...
Serina Therapeutics Makes Grants to New Employees Under Inducement Plan
11 nov. 2024 17h40 HE
|
Serina Therapeutics, Inc.
HUNTSVILLE, AL, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate SER-252 for...
Serina Therapeutics to Present at the 14th Annual Injectables Summit
02 oct. 2024 08h30 HE
|
Serina Therapeutics, Inc.
HUNTSVILLE, AL, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug...